CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for hematologists, hematology-oncology fellows, medical oncologists and other healthcare providers involved in the treatment of myelofibrosis.
  
  LEARNING OBJECTIVES

  • Use an understanding of disease biology and natural history to effectively counsel patients diagnosed with myelofibrosis (MF) about their long-term prognosis.
  • Analyze how age, performance status, prior therapeutic exposure and other biological and disease-related factors affect the selection and sequencing of therapy for patients with primary and secondary MF.
  • Appraise available research findings on the safety and efficacy of approved JAK inhibitors in patients with MF, including those with thrombocytopenia, anemia or compromised renal function.
  • Review available research data with and the current clinical role of novel JAK inhibitors for patients with MF and severe thrombocytopenia.
  • Evaluate research findings with investigational JAK inhibitors for patients with MF and anemia in preparation for the potential commercial availability of new therapeutic alternatives.
  • Develop supportive care plans to effectively monitor for, identify and manage side effects and toxicities associated with common therapies for MF.
  • Increase participation in research protocols by counseling appropriately selected patients on the biological rationale for and available efficacy and safety data with investigational agents and strategies for patients with MF.

  

  ACCREDITATION STATEMENT
  In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and Research To Practice. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
  
  PHYSICIAN CONTINUING MEDICAL EDUCATION
  Medical Learning Institute, Inc. (MLI) designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  Successful completion of this CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  
  Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).
  
  Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/SOHO2023/MF/Video/CME.
  
  CONTENT VALIDATION AND DISCLOSURES
  Medical Learning Institute, Inc. (MLI) and Research to Practice (RTP) are committed to providing their participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by MLI and RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Prithviraj Bose, MD
  Professor, Department of Leukemia
  Division of Cancer Medicine
  The University of Texas MD Anderson Cancer Center
  Houston, Texas
  
  Advisory Committee: Blueprint Medicines, GSK, PharmaEssentia; Consulting Agreements: AbbVie Inc, Blueprint Medicines, Bristol Myers Squibb, Cogent Biosciences, CTI BioPharma Corp, Geron, GSK, Incyte Corporation, Jubilant Therapeutics Inc, Karyopharm Therapeutics, Morphic Therapeutic, MorphoSys, Novartis, PharmaEssentia, Sumitomo Dainippon Pharma Oncology Inc; Contracted Research: Blueprint Medicines, Bristol Myers Squibb, Cogent Biosciences, CTI BioPharma Corp, Disc Medicine, Geron, Incyte Corporation, Ionis Pharmaceuticals Inc, Janssen Biotech Inc, Kartos Therapeutics, MorphoSys, Sumitomo Dainippon Pharma Oncology Inc, Telios Pharma Inc.
  
  Andrew T Kuykendall, MD
  Assistant Member, Department of Malignant Hematology
  Moffitt Cancer Center
  Assistant Professor, Department of Oncologic Sciences
  University of South Florida
  Tampa, Florida
  
  Advisory Committee: AbbVie Inc, Blueprint Medicines, Bristol Myers Squibb, Cogent Biosciences, CTI BioPharma Corp, Incyte Corporation, PharmaEssentia; Consulting Agreements: AbbVie Inc, GSK, KartosTherapeutics, MorphoSys, Protagonist Therapeutics; Contracted Research: Bristol Myers Squibb, GSK, Janssen Biotech Inc, MorphoSys, Protagonist Therapeutics; Data and Safety Monitoring Board/Committee: Geron.
  
  SURVEY PARTICIPANTS
  Aaron T Gerds, MD, MS — Advisory Committee: AbbVie Inc, Bristol Myers Squibb, CTI BioPharma Corp, GSK, Imago BioSciences, Kartos Therapeutics, Merck, MorphoSys, Rain Oncology, Sierra Oncology, Sobi.
  
  Professor Claire Harrison — Consulting Agreements: AbbVie Inc, AOP Health, Bristol Myers Squibb, Celgene Corporation, CTI BioPharma Corp, Galecto, Geron, Gilead Sciences Inc, GSK, Imago BioSciences, Janssen Biotech Inc, Karyopharm Therapeutics, Keros Therapeutics, MorphoSys, Novartis, Promedior Inc, Roche Laboratories Inc, Shire, Sierra Oncology; Contracted Research: AbbVie Inc, Bristol Myers Squibb, CTI BioPharma Corp, Geron, GSK, Imago BioSciences, Janssen Biotech Inc, Karyopharm Therapeutics, Keros Therapeutics, MorphoSys, Novartis; Data and Safety Monitoring Board/Committee: Keros Therapeutics; Speakers Bureau: AbbVie Inc, AOP Health, Bristol Myers Squibb, CTI BioPharma Corp, GSK, MorphoSys, Novartis; Trustee: Blood Cancer UK.
  
  Ruben A Mesa, MD — Advisory Committee: AbbVie Inc, Geron, Incyte Corporation, Telios Pharma Inc; Consulting Agreements: Blueprint Medicines, Bristol Myers Squibb, Celgene Corporation, CTI BioPharma Corp, Genentech, a member of the Roche Group, GSK, Incyte Corporation, MorphoSys, Novartis, Protagonist Therapeutics, Sierra Oncology; Contracted Research: Blueprint Medicines, Bristol Myers Squibb, Celgene Corporation, CTI BioPharma Corp, Incyte Corporation, Sierra Oncology; Data and Safety Monitoring Board/Committee: Geron, Telios Pharma Inc.
  
  MODERATOR
  John Mascarenhas, MD
  Director, Adult Leukemia Program
  Professor of Medicine
  The Tisch Cancer Institute
  Icahn School of Medicine at Mount Sinai
  New York, New York
  
  Advisory Committee: CTI BioPharma Corp, Geron, Incyte Corporation, MorphoSys; Consulting Agreements: AbbVie Inc, Bristol Myers Squibb, Celgene Corporation, CTI BioPharma Corp, Geron, Imago BioSciences, Incyte Corporation, Kartos Therapeutics, Karyopharm Therapeutics, Merck, MorphoSys, Novartis, Pfizer Inc; Contracted Research: AbbVie Inc, Bristol Myers Squibb, CTI BioPharma Corp, Geron, Incyte Corporation, Kartos Therapeutics, Karyopharm Therapeutics, Novartis; Data and Safety Monitoring Board/Committee: Galecto, Incyte Corporation.
  
  All of the relevant financial relationships listed have been mitigated.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, do not have any relevant financial relationships to disclose with ineligible companies.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This CE activity is supported through educational grants from Bristol Myers Squibb, CTI BioPharma Corp, and GSK.
  
  Release date: October 4, 2023
  Expiration date: October 5, 2024
  
  After completing the post-test, learners may download and review the answers here in order to identify further areas of study.